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INTRODUCTION
Cien pesos, por favor. For approximately five U.S. dollars 1, anyone
can walk out of a pharmacy in Mexico with a week’s worth of pills.2
And in many cases, these same pills are manufactured in the United
States (“U.S.”) and then packaged in Mexico. 3 The only difference is
the price. Generally, drug prices in international markets are
significantly less than prices in the U.S. 4 For example, a pill of the
1. USD
to
MXN
Exchange
Rate,
BLOOMBERG,
https://www.bloomberg.com/quote/USDMXN:CUR (last visited June 21, 2018).
2. See Kerry Ann Baker, Drug Costs in the U.S. vs. Mexico, VENTANAS MEX.
(Jan. 26, 2019, 12:05 PM), https://www.ventanasmexico.com/new-page-4/ (assessing
the average cost in Mexico for the exact same medicine that is available in the U.S.);
see also INFOGRAPHIC: Prescription Drug Cost Comparison, the U.S. v. Abroad,
INT’L LIVING (Jan. 26, 2019, 12:45 PM), https://internationalliving.com/prescriptiondrug-cost-comparison-the-u-s-v-abroad/.
3. Baker, supra note 2.
4. See Ben Hirschler, How the U.S. Pays 3 Times More for Drugs, SCI. AM.,
https://www.scientificamerican.com/article/how-the-u-s-pays-3-times-more-fordrugs/ (last visited Mar. 30, 2019) (reporting on research showing that U.S. prices
were consistently higher than those found in European markets, and that U.S. prices
“were six times higher than in Brazil and 16 times higher than the average in the
lowest-price country, which was usually India.”); see also Erin Alberty, To fight high
drug prices, Utah will pay for public employees to go fill prescriptions in Mexico,
SALT LAKE TRIB. (Oct. 28, 2018), https://www.sltrib.com/news/2018/10/28/fighthigh-drug-prices/ (reporting the price disparity between drugs found in the U.S. and
Mexico and, as one example, noting that Avonex, a drug which treats Multiple
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popular erectile dysfunction drug Viagra is 15$ U.S. dollars in a Tijuana
pharmacy 5 compared to $92 U.S. dollars in a San Diego pharmacy. 6 In
addition, the same innovative drug found in U.S. pharmacies may have
multiple different brand names in other countries, helping to expand
access to patients from all socioeconomic backgrounds.
There is near unanimity amongst Americans that drug prices are
out of control; innovative medicines can be far too costly for the
average person. And in their search for solutions, Republicans and
Democrats alike understandably focus most of their attention on the
mechanics of the U.S. healthcare system. An unintended consequence
of this narrow focus is that less attention is paid to potential solutions
in international markets where the same drugs sold in the U.S. are often
priced as much as 80% less. The problem of drug pricing in the U.S. is
not merely a matter of industry lobbyists having inordinately strong
power. Rather, the stark differences in pricing between U.S. and
international markets is better explained by the structural differences
between countries’ healthcare systems, laws, and regulations.
For example, U.S. federal law requires Medicare 7 and Medicaid to
reimburse most FDA-approved drugs—and this impacts the
government’s overall expenditures on healthcare if no health-outcomes
are required as a condition of reimbursement. 8 Often, this system
pushes up healthcare expenditures because the cost of reimbursing
these new drugs exceeds the cost of treating the disease. 9 In contrast,

Sclerosis, costs about $4,500 less in Mexico); Bram Sable-Smith, U.S. versus $600 in
Mexico. But is it legal?, KAISER HEALTH NEWS (Feb. 12, 2019),
https://khn.org/news/americans-cross-border-into-mexico-to-buy-insulin-at-afraction-of-u-s-cost/ (reporting that a three-month supply of insulin to treat a child’s
diabetes would cost $600 in Mexico, but the same supply would cost $3,700 in the
U.S.).
5. Interview with Pharmacist, Meds 4 Less Pharmacy, in Tijuana, Mex. (Oct.
28, 2018) (on file with author).
6. Interview with Pharmacist, Walgreens, in Encinitas, Cal. (Nov. 12, 2018) (on
file with author).
7. See Paige Winfield Cunningham, Here’s why it’s difficult to lower U.S. drug
prices, WASH. POST (May 4, 2018), https://www.washingtonpost.com (arguing that
Medicare coverage accounts for less than 15% of the U.S. population and it is for the
elderly and disabled).
8. See 42 U.S.C. § 1395w-104(b)(3)(G)(iv) (2017).
9. See generally Nisarg A. Patel, Fee-for-Value in the Pharmaceutical Industry:
A Policy Framework Applying Data Science to Negotiate Drug Prices, J.L.
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most European countries have requirements for national reimbursement
coverage. 10 For example, the United Kingdom (“U.K.”) model imposes
health-outcome requirements on manufacturers; they must demonstrate
the economic benefit of new drugs to be eligible for national
reimbursement consideration. 11
Countries also vary regarding their private sector coverage of
drugs. The U.S. private sector’s tiered pricing structure of healthcare
insurance drives pharmaceutical pricing and patient access to
innovative medicines, and some states impose coverage mandates for a
particular class of drugs. 12 However, internationally, private sector
insurance coverage requirements vary based on that country’s
healthcare model. 13
In many international markets, the most innovative drugs are paid
in cash by consumers; this triggers supply and demand mechanisms that
impact patient access. 14 Consequently, a company cannot charge more
than the market can bear. For example, patients pay out-of-pocket for
their medications in most emerging markets. 15 Therefore, innovative

BIOSCIENCES 205, 206 (2017), https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5570706/pdf/lsx002.pdf; see also Lee B. Staley, Note, A Drug’s Worth: Why
Federal Law Makes it Hard to Pay for Pharmaceutical Performance, 98 B.U. L. REV.
303, 304 (2018).
10. Rachel E. Sachs, Delinking Reimbursement, 102 MINN. L. REV. 2307, 2339
(2018) (discussing the pros and cons of delinking FDA approval to reimbursement
along with lessons from other countries).
11. Id. at 2340.
12. Id. at 2319.
13. Dana O. Sarnak et al., Paying for Prescription Drugs Around the World:
Why is the U.S. an Outlier?, THE COMMONWEALTH FUND (Oct. 17, 2:30 PM),
https://www.commonwealthfund.org/sites/default/files/documents/___media_files_p
ublications_issue_brief_2017_oct_sarnak_paying_for_rx_ib_v2.pdf.
14. See Patricia M. Danzon, Affordability and Accessibility to Medicines in
EMs: Differential Pricing is the Solution ISBINSIGHT, Apr.–June 2016, at 1,
http://isbinsight.isb.edu/affordability-and-accessibility-to-medicines-in-emsdifferential-pricing-is-the-solution/; see also Rachel Howard, Understanding Patient
PARTNERSHIP
(Oct.
14,
2015),
Willingness
to
Pay,
RES.
https://www.researchpartnership.com/resources/2015/10/article-understandingpatient-willingness-to-pay/.
15. See Howard, supra note 14; see also Emerging Market Economy,
INVESTING ANSWERS, https://investinganswers.com/financial-dictionary/worldmarkets/emerging-market-economy-1518 (last visited Sept. 22, 2018) (explaining
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drugs are competitively priced in these countries, and companies adopt
a multitude of inter and intra-country pricing strategies to optimize
patient access. 16
Drug manufacturers claim that their U.S. pricing practices are
necessary to offset research and development (“R&D”) expenditures; 17
in other words, these pricing practices are necessary to fuel innovation.
But, this claim raises an important question: how can these same
pharmaceutical companies that conduct business outside of the U.S. sell
the same innovative pill abroad at different prices and still be highly
profitable?
If the arguments against drug price controls are true, then the U.S.
would be the most innovative country, given it predominately does not
regulate pharmaceuticals prices. 18 However, countries such as the U.K.
and Canada dispel this argument because, although the drug prices in
the U.K. and Canada are significantly less than in the U.S., its
pharmaceutical industries continue to be highly profitable and innovate
in their respective countries. 19
The pharmaceutical industry has one of the highest profit margins
of any industry, and this is essential for investors because it shows
reinvesting capabilities 20 to sustain profitability growth. 21 For
example, in 2013, this industry’s average profit margin was around 20%
with some global drug companies exceeding a 40% profit margin. 22

that an emerging market is a country with an economy that is progressing through
rapid growth and industrialization).
16. See infra Part II.
17. Donald W. Light & Rebecca Warburten, Demythologizing the High Costs
of Pharmaceutical Research, 6 BIOSOCIETIES 34, 34–35 (2011).
18. Salomeh Keyhani et al., U.S. Pharmaceutical Innovation in an International
Context, 100 AM. J. PUB. HEALTH 1075, 1078 (2010).
19. Id.
20. See Geri Stengel, Profit is Nice. Margins are Even Better, INTUIT
QUICKBOOKS, https://quickbooks.intuit.com/r/financial-management/profit-is-nicemargins-are-even-better/ (last visited Nov. 17, 2018) (emphasizing that profit margins
positively impact reinvestment opportunities more than other measures of growth).
21. Richard Anderson, Pharmaceutical industry gets high on fat profits, BBC
NEWS (Nov. 6, 2014), https://www.bbc.com/news/business-28212223 (describing
the pharmaceutical industry’s profit margins relative to other major industries).
22. Id.

Published by CWSL Scholarly Commons, 2019

5

California Western International Law Journal, Vol. 49, No. 2 [2019], Art. 5
Daveler camera ready (Do Not Delete)

5/7/2019 10:14 AM

396 CALIFORNIA WESTERN INTERNATIONAL LAW JOURNAL [Vol. 49
These margins are comparable to the banking industry and are two to
three times greater than the auto, oil and gas, and media industries. 23
It is important to point out that the majority of the pharmaceutical
industry’s expenses are not from R&D. 24 Drug companies spend far
more on marketing drugs—twice as much in some cases—than on
developing them. 25 For example, global companies generally spend 20
to 30% of their revenue on sales and marketing expenditures compared
to 10 to 20% on R&D. 26 Although U.S.-based multi-national
companies are pursuing strategies to develop new drugs abroad, 27
committed R&D resources are well short of those devoted to sales and
marketing efforts internationally. 28 Therefore, the U.S., home to much
of the world’s drug development, is paying the bill for the same
innovative medicine found in pharmacies around the globe. In effect,
this amounts to the U.S. subsidizing drug development for the nations
of the world.
U.S.-based multinational companies are turning a profit in the
international markets by deploying targeted commercial strategies and
partnerships that expand patient access to innovative medicines. 29 Why
are these strategies not employed in the U.S. market? Meaningful drug
price reform efforts must consider the policies and practices outside the
U.S. and how these policies can contribute to U.S. reform efforts
towards patient access to innovative medicines.
Much ink has been spilled on the subject of U.S. drug pricing
reform—a Google Scholar search on this topic yields close to 500,000
articles. 30 This Note, however, focuses on the drug pricing and policy
models implemented internationally and highlights strategies published
by leading authorities. In turn, this Note proposes that many of these
23. See id.
24. Id.
25. Id.
26. Id.
27. Guido Reger, Internationalization of Research and Development in
Pharmaceuticals, in CHANGING INNOVATION IN THE PHARMACEUTICAL INDUSTRY 97,
97–98 (A. Jungmittag et al. eds., 2000).
28. See Anderson, supra note 21; see also Richard Levy, The Role and Value
of Pharmaceutical Marketing, 3 ARCHIVES FAM. MED. 327, 330 (1994).
29. See infra Part II.
GOOGLE SCHOLAR, https://scholar.google.com/scholar?hl=en&as_sdt=
30.
0%2C5&q=U.S.+drug+price+reform&btnG= (last visited Aug. 1, 2018).
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international strategies and best practices should be an integral
component to U.S. reform.
Part I of this Note provides an overview of pharmaceutical pricing
laws and regulations in several countries. Part II examines various
commercial strategies deployed in these countries and other
international markets that result in the sale of the same pill found in the
U.S. but at a significantly lower price. Part III proposes U.S. policy
reform based on innovative practices and models in international
markets. This Note concludes that for these reforms to be implemented,
the government, manufacturers, and payers must unite around a
common goal: access to innovative medicines for those in need while
reducing the overall costs to U.S. consumers.
I. OVERVIEW OF PHARMACEUTICAL PRICING LAWS AND
REGULATIONS
In general, the U.S. government does not regulate the pricing of
pharmaceuticals purchased by commercial payers and consumers. 31
The country’s retail supply chains remain largely unregulated, and drug
manufacturers implement coupon programs that help lower patients’
out-of-pocket costs. 32 However, these coupon tactics also cause patient
insurance plans to pay a higher price for more-expensive drugs. 33
On the other hand, in international markets, there is generally some
regulation of pharmaceutical pricing. 34 At present, there continues to
be a debate about U.S. drug pricing, and there is much controversy
around this topic because it is not new. 35 One of the primary focuses of
this debate is the role of the middlemen. 36 But, the middlemen, such as
31. Daniel L. Wellington & Robin Adelstein, 2018 Getting the Deal Through:
Pharmaceutical Antitrust United States, in PHARMACEUTICAL ANTITRUST (Marta
Giner Asins & Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated
2018).
32. Cunningham, supra note 5.
33. Id.
34. See infra Part I, Sections A–F.
35. Sachs, supra note 10, at 2307–09.
36. Robert Pearl, 4 Regulations that Would Terrify U.S. Drug Companies
Ahead of the U.S. 2018 Midterms, FORBES (July 16, 2018, 7:51 AM),
https://www.forbes.com/sites/robertpearl/2018/07/16/drug-companies/#6dbe76ac1
e41 (discussing the U.S. government’s drug pricing reform idea to “take out the
‘middlemen.’”).
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pharmacy benefit managers (“PBM”) and insurers, are not the sole
source of the drug pricing problem—the problem has many causes, and
it is one that needs to be addressed by the government, manufacturers,
insurers, and consumers. Although Congress has considered the issue
and continues to debate the Affordable Care Act (“ACA”), there is no
meaningful proposed national drug price reform bill likely to pass in the
short-term. 37 However, state legislators are addressing this problem;
thirty states put forth eighty drug pricing reform bills last year. 38 For
example, Massachusetts is turning to clinical evidence of improved
outcomes and economic savings for new drugs to receive coverage. 39
Despite increasing calls to regulate drug prices, critics claim that
placing U.S. price controls on innovative medicines will confine R&D
to discoveries. 40 In turn, they claim innovation will slow, and patients
in need of breakthrough medicines around the world will suffer. 41
However, innovative medicines are only useful if patients in need have
access to them.
Internationally, innovative medicines are less expensive than they
are in the U.S. 42 And many of these drugs are covered in national
healthcare plans. 43 These countries find ways to get medicines from
the U.S. or elsewhere, and they establish prices that enable increased
patient access. The next section of Part I examines several countries
around the world addressing the question of whether drug prices are
subject to regulatory control in those countries and if so, how they are
regulated.
37. See Alex Thompson & Sarah Karlin-Smith, Warren bill would get feds into
generic drug manufacturing, POLITICO (Dec. 17, 2018, 11:02 PM),
https://www.politico.com/story/2018/12/17/elizabeth-warren-bill-drugmanufacturing-prices-1067916 (discussing proposed drug pricing bills and the
challenges); Jay Hancock, Opinion, Everyone Wants to Reduce Drug Prices. So Why
Can’t We Do It?, N.Y. TIMES (Jan. 19, 2019, 3:00 PM),
https://www.nytimes.com/2017/09/23/sunday-review/prescription-drugs-prices.html.
38. Sachs, supra note 10, at 2347–48.
39. See id.
40. Id.
41. Id.
42. U.S. DEP’T OF HEALTH & HUMAN SERVICES, OFFICE OF THE ASSISTANT
SEC’Y FOR PLANNING AND EVALUATION, COMPARISON OF U.S. AND INTERNATIONAL
PRICES FOR TOP MEDICARE PART B DRUGS BY TOTAL EXPENDITURES 9, 14 (Oct. 25,
2018).
43. Id. at 5–6.
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A. Canada – Price Regulations for Patented Drugs
Patented drug prices are regulated. 44 Canada’s Patented Medicine
Prices Review Board (“PMPRB”) examines several key factors: (1) the
new product’s therapeutic advantage over other products; (2) drug
prices in the same therapeutic class; and (3) reference prices in other
countries. 45 Canada continues to evolve its pharmaceutical pricing
regulations by assessing the same drugs sold in lower-priced countries
while also steering towards pharmacoeconomic evaluations. 46
Therefore, Canada is moving in the direction of other countries by
adopting drug price reforms such as international reference pricing and
health outcome requirements.
B. Mexico - Moderate Drug Price Regulations
Mexico’s drug prices are subject to limited regulatory control; only
some drugs are regulated, and even still, the extent of the regulatory
control is limited. The Coordinating Commission for the Negotiation
of Prices of Medicines and Supplies for Health (“Commission”)
primarily oversees the negotiation of drug prices and related supplies. 47
The Commission’s pricing scope focuses on single source 48 or patentprotected medicines. 49 However, this Commission lacks the authority

44. Kevin Ackhurst et al., 2018 Getting the Deal Through: Pharmaceutical
Antitrust Canada, in PHARMACEUTICAL ANTITRUST (Marta Giner Asins & Yann
Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018).
45. Id.
46. See
id.;
see
also
Pharmacoeconomics,
NATURE.COM,
https://www.nature.com/subjects/pharmacoeconomics (last visited Apr. 2, 2019)
(defining pharmacoeconomics as “the scientific discipline concerned with the cost and
value of drugs, often with the goal of optimizing the allocation of healthcare
resources.”).
47. Ricardo Arturo Pons Mestre et al., 2018 Getting The Deal Through:
Pharmaceutical Antitrust United States, in PHARMACEUTICAL ANTITRUST (Marta
Giner Asins & Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated
2018).
48. Single Source Drug Law and Legal Definition, U.S. LEGAL,
https://definitions.uslegal.com/s/single-source-drug/ (last visited Sept. 22, 2018)
(explaining that a single source medicine refers to a drug produced under an original
new drug application approved by the country’s regulatory agency).
49. Mestre et al., supra note 47.

Published by CWSL Scholarly Commons, 2019

9

California Western International Law Journal, Vol. 49, No. 2 [2019], Art. 5
Daveler camera ready (Do Not Delete)

5/7/2019 10:14 AM

400 CALIFORNIA WESTERN INTERNATIONAL LAW JOURNAL [Vol. 49
to impose final prices. 50 Instead, the Commission either negotiates how
specific products will be priced and sold to consumers or it negotiates
prices with the manufacturer. 51 For example, a manufacturer with a
patented drug must justify its pricing changes before the Commission.52
Mexico’s private and public markets make access to affordable and
innovative drugs possible. Because people generally pay for medicines
out-of-pocket in the private market, pharmaceutical companies
implement innovative commercial and pricing strategies causing the
same pill sold in the U.S. to be significantly less expensive in Mexico. 53
In the public market, the government establishes competitive bidding
procedures to drive prices down. 54 For innovative medicines,
formulary access is health economics driven. 55 If companies want to
place new products in the government formulary, they must prove the
economic value of the products while also pricing them in most cases
below U.S. prices. 56
C. Brazil – Categorized Drug Price Regulations
Brazil’s private market price controls vary depending on the type
of pharmaceutical product pursuing market registration. In the public
market, the government establishes competitive bidding procedures to
drive prices down. 57 For innovative medicines, formulary access is
price-driven. 58 In 2003, Brazil’s legislature defined rules for the
pharmaceutical sector and created the Chamber of Drug Market

50. Id.
51. Id.
52. Id.
53. See Baker, supra note 2.
54. Cynthia Irene Osio Sanchez & Roberto Hernández Garcia, 2018 Getting the
Deal Through: Public Procurement Mexico, in PUBLIC PROCUREMENT (Totis
Kotsonis ed., Law Bus. Research 2018), Lexis (database updated 2018).
55. Pierre Moïse & Elizabeth Docteur, Org. for Econ. Co-operation & Dev.
[OECD], Pharmaceutical Pricing and Reimbursement Policies in Mexico 19–20,
No.
25,
Feb.
13,
2007),
(OECD
Health
Working
Papers
https://dx.doi.org/10.1787/302355455158.
56. See id.
57. See id. at 21.
58. See id. at 19–20.
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Regulation (“CMED”), 59 which sets drug prices according to criteria
contained in six categories. 60 These categories and criteria are in the
following table. 61

59. Alexandre Ditzel Faraco et al., 2018 Getting the Deal Through:
Pharmaceutical Antitrust Brazil, in PHARMACEUTICAL ANTITRUST (Marta Giner
Asins & Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018).
60. Memorandum from The Daveler Group, Inc. on CMED Policies and
Criteria for Price Control in Brazil to Orexigen Therapeutics, Inc. (May 23, 2016)
[hereinafter The Daveler Group] (on file with author).
61. Id.
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CHAMBER OF DRUG MARKET REGULATION’S CATEGORY
AND PRICING CRITERIA
Category
I

II
III

IV

V

VI

Criteria
New patent-protected drugs:
Launch price set by external reference pricing, not to exceed
the drug’s lowest price in Australia, Canada, France, Greece,
Italy, New Zealand, Portugal, Spain, the U.S., and the country
of origin.
“Me-too” drugs: 62
Launch price established by cost minimization approach.
New presentation, in the same dosage form, of an already
marketed drug:
Launch price based on the average prices of already marketed
drugs.
New presentation, in a different dosage form, of an already
marketed drug:
Launch price not to exceed the average price, weighted by
sales, of available presentations of the drug that have the same
active ingredients, strength, and dosage.
New combination of active ingredients already available in
Brazil:
Launch price not to exceed the drug’s lowest price in any of
the Category I countries.
Generic drugs:
Launch price not to exceed 65% of the respective reference
product’s price.

CMED’s categorized price regulation helps the government control
drug prices. And despite these regulations, Brazil’s growing industry
and economy make the country a priority for companies to
commercialize their products.

62.
See Medical Definition of Me-too Drug, MEDICINENET,
https://www.medicinenet.com/script/main/art.asp?articlekey=33748 (last visited
Sept. 22, 2018) (explaining that a me-too drug is a drug that is duplicative or very
similar to already known drugs).
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D. India – Price Regulations for Formulary and Essential Drugs
The National Pharmaceutical Pricing Authority (“NPPA”)
regulates drug prices. 63 The NPPA is governed under the Drug Price
Control Order where scheduled medicines (government formulary
drugs), including essential drugs, 64 have a ceiling retail price and are
under regulatory control. 65 India’s government also establishes the
ceiling retail price of any drug, scheduled or non-scheduled, or of a new
drug if the country deems it is in the public interest. 66
E. South Korea – Price Regulations if Drug Reimbursed
The National Health Insurance (“NHI”) system reimburses most
drugs. 67 Under this system, the NHI negotiates with the manufacturer
and, based on the NHI’s standards, establishes the maximum
reimbursement price (“MRP”). 68 The NHI governs any adjustments to
the MRP, and its procedures are established by legislation. 69 All
reimbursed drugs are regulated in Korea. 70
F. Turkey – Price Regulations Through Reference Drug Pricing
Turkey’s Ministry of Health holds legislative powers to issue
pricing guidelines and establish regulations. 71 The government
implements reference pricing by benchmarking drug prices found in

63. Samar R. Gandhi et al., 2018 Getting the Deal Through: Pharmaceutical
Antitrust India, in PHARMACEUTICAL ANTITRUST (Marta Giner Asins & Yann Anselin
eds., Law Bus. Research 2018), Lexis (database updated 2018).
64. Id.
65. Id.
66. Id.
67. Kyung Shik Roh et al., 2018 Getting the Deal Through: Pharmaceutical
Antitrust Korea, in PHARMACEUTICAL ANTITRUST (Marta Giner Asins & Yann
Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018).
68. Id.
69. Id.
70. Id.
71. Gönenç Gürkaynak & K. Korhan Yıldırım, 2018 Getting the Deal Through:
Pharmaceutical Antitrust Turkey, in PHARMACEUTICAL ANTITRUST (Marta Giner
Asins & Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018).
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France, Greece, Italy, Portugal, and Spain. 72 In turn, innovative
pharmaceuticals sold in Turkey may not exceed the lowest reference
country price. 73
G. United Kingdom – Price Regulations if Drug Reimbursed
Patient access to medicines is controlled jointly by U.K.’s National
Health Services (“NHS”) and the National Institute for Health and Care
Excellence (“NICE”). 74 NICE requires manufacturers to provide
rigorous health outcome data, including pharmacoeconomics, before a
new drug is granted clearance into formulary. 75 The U.K. controls drug
prices through a Pharmaceutical Price Regulation Scheme (“PPRS”) or
the parallel statutory scheme. 76
Under the PPRS protocol,
pharmaceutical companies enter a risk-sharing model with the
government where drug manufactures rebate to the government excess
drug expenditures. 77 Manufacturers who do not participate in the PPRS
scheme are subject to statutory requirements. 78
Under these
requirements, the government must approve a new pharmaceutical
product’s price along with any price increases. 79
H. Summary - Majority of Countries Instill Price Regulations
Most countries outside the U.S. impose drug price regulations, but
the U.S. generally does not. 80 While drug price policies outside the

72. Id.
73. Id.
74. John Schmidt et al., 2018 Getting the Deal Through: Pharmaceutical
Antitrust United Kingdom, in PHARMACEUTICAL ANTITRUST (Marta Giner Asins &
Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018).
75.
Developing
and
updating
local
formularies,
NICE,
https://www.nice.org.uk/guidance/mpg1/chapter/recommendations#processes-forselecting-medicines-to- be-considered-for-inclusion-in-the-local-formulary (last
visited Jan. 20, 2019) (overview of process for selecting of medicine into the local
formulary).
76. Schmidt et al., supra note 74.
77. Id.
78. Id.
79. Id.
80. See Wellington & Adelstein, supra note 31.
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U.S. vary, most are driven by similar factors including but not limited
to drug type, international reference pricing, and reimbursement. 81
Although many other countries impose strict drug pricing
regulations, pharmaceutical companies still manage to generate
substantial profit. Part II of this Note examines various drug
manufacturers’ tactics that enable them to still turn a profit despite
significantly discounted drug prices. The remainder of Part II
highlights some leading literature on these strategies and this author’s
experience in implementing them.
II. COMMERCIAL STRATEGIES ABROAD
Various commercial strategies are deployed in countries outside the
U.S. to sell the same drugs found in the U.S. but at significantly lower
prices. Drug manufacturers’ strategies focus on increasing market
access to their drugs in large populations while still earning a profit. In
doing so, pharmaceutical companies execute inter and intra-country
differential pricing tactics and R&D partnership strategies.
A. Inter-Country Differential Pricing Strategies
In response to innovation and increasing patient access to drugs, the
industry engages in inter-country differential pricing. 82 Inter-country
differential pricing occurs where a company sells a particular drug for
one price in one country and then sells that same drug at a significantly
different price in another country. 83 The World Health Organization
supports this approach because it ensures greater access to innovative
medicines in developing countries. 84
When manufacturers implement differential pricing strategies, they
can increase patient access to life-saving pharmaceuticals by up to
seven times—and these strategies do not prevent manufactures from
81. See Ackhurst et al., supra note 44.
82. Brianna Carignan, Legalizing Importation of Prescription Drugs: The
Economic Implications of the Pharmaceutical Market Access and Drug Safety Act of
2005, 12 NEW ENG. J. INT’L & COMP. L. 161, 178 (2005).
83. See Quentin A. Palfrey, Expanding Access to Medicines and Promoting
Innovation: A Practical Approach, 24GEO. J. POVERTY L. & POL’Y 161, 169–70
(2017) (discussing manufacturers international pricing strategies).
84. Carignan, supra note 82, at 179.

Published by CWSL Scholarly Commons, 2019

15

California Western International Law Journal, Vol. 49, No. 2 [2019], Art. 5
Daveler camera ready (Do Not Delete)

5/7/2019 10:14 AM

406 CALIFORNIA WESTERN INTERNATIONAL LAW JOURNAL [Vol. 49
maintaining a strong profit margin. 85 For example, consumers in lowincome countries buy drugs at or below the manufacturer’s marginal
cost which expands the patient-base of pharmaceutical companies. As
a result, drug demand and production increases, which help
manufacturers reduce their overall costs. 86 Countries’ tiered pricing is
customary where depending on the drug, companies charge a tier one
country one price and a tier two country a different price. 87 Companies
recoup any lost profit in the lower tier or developing countries by
pricing the same drug at a premium in wealthy countries. 88 Consumers
in high-income countries, such as the U.S., argue such differential
pricing is unfair. 89 However, this pricing strategy merely provides
advantages to consumers in poorer countries, such as emerging
markets, to access innovative medicines.
B. Intra-Country Differential Pricing Strategies
Pharmaceutical manufacturers also deploy intra-country
differential pricing strategies, particularly in emerging markets. 90 Intracountry differential pricing is when a company sells its drug at a certain
price in one area or market segment of the country and then sells the
same drug for a significantly different price in another area or market
segment of the country. 91
Pharmaceutical companies over the last several years have
designated emerging markets as critical to their growth. 92 With affluent
populations and a growing middle class, these emerging markets are a
85. Id.
86. Id.
87. See Palfrey, supra note 83, at 169; see also HIV and Aids: bad news for
drug prices in middle-income countries, GUARDIAN (July 22, 2011),
https://www.theguardian.com/global-development/2011/jul/22/hiv-aidsantiretroviral-drugs-pricing (providing instances in which HIV drugs were offered at
reduced prices in low and middle-income countries).
88. Carignan, supra note 82, at 179.
89. Id.
90. Palfrey, supra note 83, at 171.
91.
Prashant Yadav, Differential Pricing for Pharmaceuticals, MITINT’L
LOGISTICS
PROGRAM,
42–43
(2010),
ZARAGOZA
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachm
ent_data/file/67672/diff-pcing-pharma.pdf
92. Palfrey, supra note 83, at 171.
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focus for companies to accelerate market entry for innovative products
and executing commercial strategies. For example, Brazil and India are
emerging markets where drug manufacturers are investing significant
resources. 93 These countries are becoming common second priority
targets behind the first priority U.S. and Europe for pharmaceutical
product launches. 94
Intra-country differential pricing helps to both maximize company
profits and expand patient access to medicines. 95 However, one risk
that emerges from this strategy is the possibility of physical arbitrage.
Drug manufacturers implement multiple commercial strategies 96 to
mitigate the physical arbitrage 97 risks. Common tactics in emerging
markets include the use of different brand names and packaging to
different channels that reach more people. 98 This approach is where
one brand has the same trademark as marketed in the U.S. and is priced
at a premium, and the other brand has a local trademark and is priced
significantly lower. 99 For example, in Mexico, Farmacias de Similares
markets its pharmacy chains with the slogan, “Lo Mismo Pero Mas
Barato” 100 (the same but much cheaper), and it targets the country’s
poor consumers by selling its own private label of a manufacturer’s

93. Brazil, Russia, India, and China (BRIC) Becoming Popular Second Wave
10,
2017),
Targets,
Recent
Study
Finds,
MKT. WIRED (May
http://www.marketwired.com/press-release/brazil-russia-india-china-bric-becomingpopular-second-wave-targets-recent-study-finds-2215496.htm.
94. See id.
95. See Palfrey, supra note 83, at 171; see also Yadav, supra note 91, at 43.
96. Palfrey, supra note 83, at 172.
97. Kevin Outterson, Pharmaceutical Arbitrage: Balancing Access and
Innovation in International Prescription Drug Markets, 5 YALE J. HEALTH POL’Y L.
& ETHICS 193, 205–06 (2005) (explaining that arbitrage is the practice of taking
advantage of price differences in two or more markets).
98. See Ram Subramanian & Rehnan Baqri, Branding: When One is Not
Enough, PHARMAEXEC.COM (Feb. 3, 2016), http://www.pharmexec.com/brandingwhen-one-not-enough (discussing second brand strategy for pharmaceuticals
particularly in emerging markets); see also Rutger Daems et al., Global Framework
for Differential Pricing of Pharmaceuticals 21 (UNU-Merit Working Paper No. 2011054),
https://www.merit.unu.edu/publications/working-papers/abstract/?id=4557;
Palfrey, supra note 83, at 173–74.
99. See Subramanian & Baqri, supra note 98.
100. FARMACIAS SIMILARES, https://farmaciasdesimilares.com/#!/ (last visited
Aug. 2, 2018).
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innovative drug. 101 In doing so, Farmacias de Similares dramatically
reduces its private label drug prices compared to other pharmacy chains
such as Farmacias Benavides, where the same drug will be sold under
a brand name at a premium price to the wealthy consumer. 102
This intra-country differential pricing strategy works well in
international markets where people predominately pay out-of-pocket
because such innovative commercial practices increase patient access
and manufacturers’ profits. 103 Therefore, in those countries—where
poor and wealthy people live side-by-side—intra-country differential
pricing offers great promise. 104
C. Research and Development Strategies and Partnerships
Pharmaceutical companies are also expanding their R&D strategies
through international partnerships to accelerate market approval for
their innovative medicines both in the U.S. and abroad. 105 If
manufacturers in the U.S. use foreign research data provided through
these partnerships, it can shorten the time to bring new life-saving
medicines to the U.S. market. 106 However, Congress requires the Food
and Drug Administration (“FDA”) to oversee the safety and efficacy of
drugs sold in the U.S. 107 The FDA must balance the benefit of
innovative drugs coming to market faster through the use of foreign

101. See David Luhnow, Maker of Generics Adds Spice to Drug Business,
WALL STREET J., https://www.wsj.com/articles/SB110833733909653530 (last
updated Feb. 14, 2005, 12:01 AM).
102. See FARMACIAS BENAVIDES, http://www.benavides.com.mx (last visited
Oct. 28, 2018).
103. Subramanian & Baqri, supra note 98.
104. Palfrey, supra note 83, at 194.
105. Michelle Palmer & Rathnam Chaguturu, Academia-Pharma Partnerships
for Novel Drug Discovery: Essential or Nice to Have? 12 EXPERT OP. ON DRUG
DISCOVERY 537, 538 (2017).
106. See FDA’s Legal Authority, FDA, https://www.fda.gov/AboutFDA/
History/FOrgsHistory/EvolvingPowers/ucm593384.htm (last visited Feb. 2, 2019).
107. See John J. Gorski, Comment, An FDA-EEC Perspective on the
International Acceptance of Foreign Clinical Data, 21 CAL W. INT’L L.J. 329, 331–
33 (1990); see also Premnath Shenoy, Multi-Regional Clinical Trials and Global
CLIN
RES.
62
(Mar.
31,
2016),
Drug
Development,
PERSP.
http://www.picronline.org/temp/PerspectClinRes7262-7532148_205521.pdf.
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research data with its mission of ensuring safety and reliability. 108
While the FDA is tasked with striking an appropriate balance in this
context, another factor the FDA should consider is that the economy is
becoming increasingly globalized, and technological innovation is
increasing in markets around the world. The U.S. must look beyond its
borders for solutions to benefit its citizens. Global R&D partnerships
that develop innovative and cost-effective solutions will better serve the
needs of patients in the U.S. and abroad.
For example, pharmaceutical companies are becoming increasingly
interested in biosimilars, 109 and international partnerships are forming
around this mutual interest. These drugs provide access to twice as
many patients because biosimilars are half of the price of the original
drug. 110 Further, biosimilars provide patient access to lifesaving drugs.
Since these types of drugs are significantly less expensive, a company
can expand its novel drug’s global access while still earning a profit.111
Internationally, biosimilars are in high demand and offer another
strategy to achieve corporate business goals. 112
Pharmaceutical innovation is also on the rise in emerging markets.
For example, in India, companies are discovering new medicines using
state-of-the-art technologies. 113
Research and development
partnerships are being formed to tap into the unique and large
108. See generally Acceptance of Foreign Clinical Studies – Information Sheet,
FDA
(Mar.
2012),
https://www.fda.gov/RegulatoryInformation/Guidances/
ucm126426.htm (last visited Feb. 3, 2019) (providing a review of the FDA’s
guidelines regarding foreign clinical studies).
109. See
Biosimilars
and
Interchangeable
Products,
FDA
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDeveloped
andApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/u
cm580419.htm#biosimilar (last visited Sept. 22, 2018) (defining biosimilars as “a
biological product that is highly similar to and has no clinically meaningful difference
from an existing FDA-approved reference product.”).
110. Guy Martin, Biocad goals go beyond putting Russian biotech on the map,
PHARMA LETTER (Nov. 29, 2016), https://www.thepharmaletter.com/article/biocadgoals-go-beyond-putting-russian-biotech-on-the-map.
111. Id.
112. Bruno Calo-Fernández & Juan Leonardo Martínez-Hurtado, Biosimilars:
Company Strategies to Capture Value from the Biologics Market, 5
PHARMACEUTICALS 1393, 1400 (2012).
113. Kurt Stoeckli, India and the future of life science innovation, LIVEMINT
(Dec.
29,
2017),
https://www.livemint.com/Opinion/DOlDi0nGh
JVWUX1NFlHOrK/India-and-the-future-of-life-sciences-innovation.html.

Published by CWSL Scholarly Commons, 2019

19

California Western International Law Journal, Vol. 49, No. 2 [2019], Art. 5
Daveler camera ready (Do Not Delete)

5/7/2019 10:14 AM

410 CALIFORNIA WESTERN INTERNATIONAL LAW JOURNAL [Vol. 49
population which is unlocking India’s biopharmaceutical potential. 114
Similar strategies are used in Russia. 115 This partnership approach
reduces costs, increases access to innovative products, and helps
expand patient access to life-saving treatments at affordable prices. 116
Innovative biopharmaceutical companies around the world striving to
accelerate innovation are now pursuing opportunities to do so
internationally. 117
D. Summary - Commercial Strategies Enable Access
Pharmaceutical drug price regulations do not necessarily hinder
patient access to innovative medicines. Global companies are
accustomed to overcoming market barriers by deploying inter and intracountry pricing strategies and other commercial tactics to gain effective
market access. Partnerships will continue to be a win-win for
governments, patients, and the industry. If such strategies are working
abroad, surely the U.S. can reform its policies to harness these
approaches. However, U.S. reform can only take place if the healthcare
system is fundamentally transformed.
Part III of this Note assesses policy options, many based on
international models, which serve to stimulate discussion on
meaningful U.S. reform. These options include increasing valueeffectiveness measures, reference-based pricing, enforcing competition
law, and pharmaceutical arbitrage. Part III concludes by outlining the
best practices internationally and proposing plausible strategies that
should be adopted in the U.S. in light of these international practices.

114. Id.
115. Taylor

Heyman, Russia: a bright future for clinical trials?,
PHARMACEUTICAL TECH. (Feb. 3, 2019, 2:30 PM), https://www.pharmaceuticaltechnology.com/features/featurerussia-a-bright-future-for-clinical-trials-4872809/.
116. See Press Release, The Challenges and Opportunities of a Foreign Drug
Registration in Russia, ARS PharmRussia Reveals, MKT. WATCH (Jan. 15, 2018, 7:45
AM), https://www.marketwatch.com/press-release/the-challenges-and-opportunitiesof-a-foreign-drug-registration-in-russia-ars-pharmrussia-reveals-2018-01-15.
117. Global Pharma continues to see potential in investing in R&D in India,
BIOSPECTRUM (July 4, 2017), https://www.biospectrumindia.com/news/69/9197/
global-pharma-continues-to-see-potential-in-investing-in-rd-in-india.html.
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III. UNITED STATES POLICY REFORM
There are several ways that policy can be reformed in the U.S., but
these reforms would require significant legislative and regulatory
changes. 118 An open-minded approach—examining both domestic and
international strategies—is needed to address pharmaceutical pricing
reform for innovative drugs in the U.S. To be sure, proponents and
opponents exist for all of these options—and some of these areas of
disagreement will be discussed below.
A. Value-Effectiveness Policies
Instilling value-effectiveness measures is one of the most important
ways to increase effective competition among brand-name drugs. 119
One example of a value-effectiveness measure is making regulatory
approval of a new drug contingent on proving that the new medicine
saves overall health care costs. Policy experts argue that enhancing
government authority for these kinds of value assessments, broadening
substitution laws, and using evidence-based formularies will help
promote effective competition.120 However, these policy changes will
likely face challenges unless the government also institutes regulatory
changes. That is because a new drug’s market approval is currently not
dependent on reducing health care costs. 121
Currently, neither the FDA nor any U.S. government agency
conditions approval of an innovative drug based on value or cost, and
118. See Aaron S. Kesselheim et al., The High Costs of Prescription Drugs in
the United States: Origins and Prospects for Reform, 316 [J]AMA 858, 865–66
(2016); see also Eric Mershon & Ike Swetiltz, Will Trump’s Plans Bring Down Drug
AM.
(Feb.
3,
2019,
10:00
PM),
Prices?,
SCI.
https://www.scientificamerican.com/article/will-trumps-plans-bring-down-drugprices/.
119. Jonathan J. Darrow & Aaron S. Kesselheim, Policy Options Paper:
Promoting Competition to Address Pharmaceutical Prices, HEALTH AFF. 4 (Mar. 15,
2018),
https://www.healthaffairs.org/do/10.1377/hpb20180116.967310/listitem/
HPP_2018_CMWF_02_W.pdf (reviewing policy interventions to address
competition shortcomings for lowering drug prices).
120. Id. at 4–5.
121. See id. at 4; see also Randall S. Stafford et al., New, But Not Improved?
Incorporating Comparative-Effectiveness Information into FDA Labeling, 361 NEW
ENG. J. MED. 1230, 1230 (2009).
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past attempts to do so faced political opposition. 122 However, in other
wealthy countries—such as the U.K. and Germany—designated
agencies exist to evaluate the value of a new drug before the drug gains
market approval. 123
Payers have options for therapeutic substitutions to diminish highprice, low-value drugs. 124 However, for these alternatives to be
possible, drug substitution laws in the U.S. require transitioning
substitution authority from the physician to the pharmacy level. 125 Both
regulatory and cultural changes are needed to bring about this change.
Some private payers in the U.S. are also turning to valueeffectiveness policies; consequently, manufacturers need to incorporate
value-effectiveness to gain formulary inclusion. 126 For example, one
PBM provided its clients the option not to cover a new medicine
launched in the market at a price higher than $100,000 per qualityadjusted life-year (“QALY”). 127 That is, if the new drug’s launch price
was over $100,000 per QALY compared to the current standard of care
to treat the same disease, the employer’s insurance plan might not offer
that new drug to its employees. 128 In comparison, most medications in
Europe are initially launched to produce effectiveness rated at $50,000
per QALY. 129
Generally, the U.S. does not have any such value-effectiveness
threshold programs. Launch prices of new drugs in the U.S. continue
to go up each year, pushing costs per QALY into the $300,000 to
$500,000 range—costs that are not sustainable in the U.S. health care

122. Darrow & Kesselheim, supra note 119, at 4.
123. Id.
124. See id. at 4–5.
125. Id.
126. Troyen Brennan & Surya Singh, Why CVS is Giving Plans a New Tool to
Target High Launch Prices, HEALTH AFF. BLOG: CONSIDERING HEALTH SPENDING
(Sept.
17,
2018),
https://www.healthaffairs.org/do/10.1377/
hblog20180913.862850/full/.
127. See generally Do you know what a QALY is, and how to calculate it?,
C.E.L. FOR PHARMA, https://www.celforpharma.com/insight/do-you-know-whatqaly-and-how-calculate-it (last visited Nov. 17, 2018) (defining QALY and
presenting the calculation).
128. Brennan & Singh, supra note 126.
129. Id.

https://scholarlycommons.law.cwsl.edu/cwilj/vol49/iss2/5

22

Daveler: Same Pill, Different Price: The Case for Policy Reform in the Uni
Daveler camera ready (Do Not Delete)

2019]

SAME PILL, DIFFERENT PRICE

5/7/2019 10:14 AM

413

system. 130 Critics of these exorbitant costs argue that value-assessment
thresholds must factor in several considerations and new drug prices
need to reflect value. 131 Nonetheless, a value-effectiveness threshold
requiring manufacturers to give reasonable discounts from the start of
market entry for their new drug deserves consideration.
B. International Reference Pricing
International reference pricing is another policy that can be adopted
as part of efforts to reform U.S. drug pricing. As the name suggests,
international reference pricing primarily involves setting drug prices
based on the price of the same drug in other countries. 132 It is wellestablished that reference pricing controls drug reimbursement
expenditures by benchmarking the prices of identical or similar drugs
which are considered interchangeable. 133 This pricing mechanism is
Government
increasing in popularity in many countries. 134
reimbursement of drugs in a system with reference pricing is based on
the price of that same drug in other countries. 135 For example, in Brazil,
innovative patent-protected drug launch prices are established by
referencing Australia, Canada, France, Greece, Italy, New Zealand,
Portugal, Spain, the U.S., as well as the country where the drug
originated. 136 The lowest price of the new drug in any of these countries
is the price established in Brazil. 137 Other countries such as Poland and
Canada have successfully instituted reference pricing and experienced
decreases in prescription drug spending. 138

130. Id.
131. Robert Dubois, CVS to Restrict Patient Access Using Cost-Effectiveness:
Too Much, Too Soon, HEALTH AFF. BLOG: CONSIDERING HEALTH SPENDING (Sept.
17, 2018), https://www.healthaffairs.org/do/10.1377/hblog20180913.889578/full/.
132. Marie Salter, Comment, Reference Pricing: An Effective Model for the
U.S. Pharmaceutical Industry?, 35 NW. J. INT’L L. & BUS. 413, 416 (2015)
(discussing the importance of international reference pricing).
133. Id. at 416–17.
134. Id. at 426.
135. See id. at 416.
136. See The Daveler Group, supra note 60.
137. See id.
138. Salter, supra note 132, at 421.
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On the other hand, reference pricing could have a negative impact
on global research and development because the U.S. is the home to
much of the world’s innovative drug research. 139 Forcing drug prices
down in the U.S. risks reducing profits which could cause a decrease in
investments towards discovering breakthrough medicines. However,
some evidence suggests that countries with reference pricing or other
types of regulation innovate proportionally more than the U.S.140
Therefore, reference pricing does not necessarily cause a decrease in
investments toward new drug development, particularly when U.S.
federal funding continues to play an integral role in new drug
discoveries. 141 Enacting reference pricing should be part of U.S. policy
reform. In a globalized economy where such an approach has been
demonstrably successful in other countries, there is no reason why this
approach should not be adopted in the U.S. The overall positive effects
on payers and consumers outweigh any adverse effects. 142
C. Competition Law
Competition law can also be used to restrict excessive drug pricing.
For example, Canada and South Africa expressly identify charging an
excessive price a competition law violation. 143 In these countries,
companies are prohibited from selling drugs at excessive prices despite
having a patent and a monopoly position. 144 However, U.S. antitrust
jurisprudence continues to prevent the excessive pricing doctrine from
being used mostly because of the rights of the patentee to recoup
investment and sell at a price that the market will bear. 145
The United States Supreme Court has not endorsed the excessive
pricing doctrine, but the Court has made clear that a holder of a patent

139. Id. at 433.
140. Id. at 434.
141. Id.
142. Id. at 438.
143. Frederick M. Abbott, Excessive Pharmaceutical Prices and Competition
Law: Doctrinal Development to Protect Public Health, 6 U.C. IRVINE L. REV. 281,
298–99 (2016) (discussing competition law and policy to address excessive
pharmaceutical drug pricing).
144. Id.
145. Id. at 319.
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that charges excessive pricing is not immune from antitrust laws.146
Further, the Supreme Court of California puts the burden on the
patentee to justify its pricing conduct. 147 Thus, competition law and
enforcement of the excessive pricing doctrine should be used to
constrain out-of-hand drug pricing when the patentee takes advantage
of the U.S. free-market pricing system.
D. Pharmaceutical Arbitrage
Domestic intellectual property laws, reimbursement systems, and
country-specific laws affect drug prices. 148 As a result, manufacturers
establish differential pricing strategies across countries based on the
socioeconomic status and pricing regulatory framework of each
individual market. 149 It is well-documented that patented medicines in
Canada are typically cheaper than the same medicine in the U.S. 150 For
example, a patented drug sold for $10 (U.S. dollars) in Canada may be
identical to the same drug in the U.S. sold for a significantly higher
price. 151 Thus, lower-priced innovative drugs north of the U.S. border
create consumer demand for cross-border parallel-trade or
pharmaceutical arbitrage. 152
Drug imports from Canada are a textbook example of
pharmaceutical arbitrage at work. 153 The practice started when U.S.
citizens traveling to Canada for vacation or business needed to refill
their U.S. prescription. 154 This practice evolved to U.S. citizens living
close to the border embarking on trips for the specific purpose of
146. FTC v. Actavis, Inc., 570 U.S. 136, 149-50 (2013).
147. In re Cipro Cases I & II, 348 P.3d 845, 867 (2015).
148. Outterson, supra note 97, at 195 (discussing pharmaceutical arbitrage
impact on access and innovation and its implications on drug pricing and distribution).
149. For a detailed discussion of differential pricing, see Patricia M. Danzon,
Differential Pricing of Pharmaceuticals: Theory, Evidence, and Emerging Issues, 36
PHARMACOECONOMICS 1395 (2018).
150. Outterson, supra note 97, at 195.
151. See Average foreign-to-Canadian price ratio for patented drugs as of
2017, STATISTA, https://www.statista.com/statistics/496169/price-ratio-canadia-toforeign-drug-prices/ (last visited Feb. 7, 2019).
152. Outterson, supra note 97, at 195.
153. Id. at 275.
154. Id. at 276.
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obtaining lower-cost prescriptions. 155 This practice continued to
spread—bus trips were organized for people living far away from the
border, and a consumer market developed for mail order pharmacies to
acquire patented medicines. 156
The internet greatly expanded the number of people engaging in
cross-border arbitrage; the market jumped from the few million
Americans living along the Canadian border to many millions of people
throughout the U.S. 157 Despite the FDA’s efforts to block attempts to
acquire lower-cost patented drugs from Canada, consumers and
institutions are saving hundreds of millions of dollars on patented
medicines online with one click. 158
Despite these savings, federal and state actions continue to attack
pharmaceutical arbitrage. 159 But healthcare public policy must
champion access—and arbitrage encourages policy reform to take place
which, in turn, will increase affordable access. Canada and other
countries impose regulatory measures to restrict drug prices, which
forces the U.S. to evaluate alternative regulatory systems. 160 Virtual
arbitrage, or referencing other drug prices in other countries, also forces
the government to assess prices in other countries. Moreover, virtual
arbitrage is preferred to physical arbitrage because it is more resourceefficient and preserves the drug supply chain. 161 As a result, the
legislative branch is required to collaborate with the executive branch
offices such as the Secretary of Health and Human Services (“HHS”)
to enact laws and institute safe and cost-savings means to legalize the
Therefore, competitive analysis of the
arbitrage process. 162
neighboring regulatory and pricing structures of other countries
promotes reform. 163
In 2000, Congress passed the Medicine Equity and Drug Safety Act
(“MEDS Act”), which permitted the importation of prescription drugs
155.
156.
157.
158.
159.
160.
161.
162.
163.

Id.
Id.
Id.
Id. at 276–80.
Id. at 285.
Id. at 280–283.
Id.
Id. at 281.
See id. at 282.
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originally produced in the U.S. 164 This law allowed the U.S. consumer
to benefit from other lower priced medicines in other countries. 165 The
following year, however, the HHS did not certify the MEDS Act,
rendering it ineffective to concerns that pharmaceutical manufacturers
still could keep prices at high levels. 166 U.S. policy reform should
include re-assessing the MEDS Act and, if nothing else, adopting its
mission to provide patients with alternative drugs at lower prices. The
evolving global healthcare market over the last two decades justifies a
re-assessment of this approach.
E. Best Practices Abroad
U.S. drug policy reform should also incorporate the best practices
of other countries. In doing so, the U.S. healthcare system could evolve
into universal coverage while still reducing overall healthcare
expenditures. Many countries—including but not limited to Israel,
South Korea, and Canada—have moved towards universal coverage
while maintaining effective and efficient healthcare systems. 167 The
following section will highlight several countries’ best practices and
discuss how those practices could become an integral part of U.S. drug
policy reform.
1. Israel – Universal Healthcare Model
Healthcare spending in Israel as a share of gross domestic product
(“GDP”) is 7.5%; the U.S., on the other hand, spends 16.4% of GDP on
healthcare, and Israel enjoys a higher life expectancy than the U.S.168
Israel employs seven strategies under its universal healthcare system to
control drug prices. 169
164. Jonathan Ma, Lowering Prescription Drug Prices in the United States:
Are Reimportation and Internet Pharmacies the Answer?, 15 S. CAL. INTERDISC. L.J.
345, 352 (2006) (discussing and reviewing the MEDS Act).
165. Id.
166. Id. at 352–53.
167. See generally Bruce Rosen, Expanding Canadian Medicare to Include a
National Pharmaceutical Benefit While Controlling Expenditures: Possible Lessons
From Israel, 13 HEALTH ECON. POL’Y & L., 324, 324–26 (2018) (reviewing Israel’s
strategies to constrain pharmaceutical spending); see also Roh et al., supra note 67.
168. Rosen, supra note 167, at 324–25.
169. Id. at 330–36.
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First, it prioritizes new technologies that are established by a
governing board. 170 This prioritization process gives pharmaceutical
companies crucial information regarding whether their new drugs will
be included in the government program. 171 In addition, risk-sharing
agreements between the companies, government, and health plans help
ensure access to novel medicines while controlling overall costs.172
Second, significant discounts are achieved through reference pricing
implemented by the country’s health plans. 173
Third, the
pharmaceutical distribution system is efficient by capitalizing on
economies of scale. 174 Fourth, measures are in place for physicians to
avoid prescribing expensive drugs when less expensive alternatives
exist.175 Fifth, consumer drug advertising is regulated to avoid
artificially inflating consumer demand. 176 Sixth, Israel strikes a balance
between respecting intellectual property, access, and cost containment
by strictly enforcing patents while at the same time creating a generics
friendly environment. 177 Finally, Israel creates a shared societal
understanding of the values of pharmaceuticals while aligning its
citizens’ expectations through its new health technologies prioritization
process. 178
In summary, Israel’s government plays an important and active role
in its healthcare system. If U.S. policymakers seek to implement
Israel’s best practices, it would need to match this level of involvement
in the U.S. healthcare system.
2. South Korea – Price Negotiation Model
The U.S. can also look to South Korea for solutions to its drug
pricing problem. There, most drugs are reimbursed through the NHI. 179
If companies want their new medicines reimbursed, they must negotiate
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.

Id. at 331–32.
Id. at 331.
Id. at 332.
Id. at 332–33.
Id. at 333.
Id. at 333–34.
Id. at 334.
Id. at 334–35.
Id. at 335.
Roh et al., supra note 67.
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pricing with the NHI. 180 This process enables access to innovative
drugs with built-in cost-containment measures. 181 In comparison to the
South Korean model, the U.S. government would need to establish
linkage requirements between reimbursement and pricing of innovative
medicines on a broader scale than what currently exists.
3. United Kingdom – Value-Based Model
In the U.S., FDA-approved drugs are often covered by insurance.
For example, federal law requires Medicare and Medicaid to cover
most, and in many cases all, FDA-approved drugs. 182 Private payers
have similar drug coverage tied to FDA approval due to federal and
state laws. 183 This process enables access to innovative medicines, but
it also creates cost-containment problems. 184
Importantly, the U.K.—one of the most studied drug price
models—delinks drug approval and reimbursement. 185 Once the
Medicines and Healthcare Products Regulatory Agency (“MHRA”) or
the European Medicines Agency (“EMA”) approves a new drug, NICE
examines the drug’s clinical and economic benefits and makes a
recommendation to NHS regarding reimbursement. 186 This appraisal
system causes almost all innovative drugs to be less expensive than
those same innovative drugs covered in the U.S. public payer system
such as Medicare. 187 Also, the U.K. encourages partnerships between
NHS and pharmaceutical companies to develop new drugs for unmet
medical needs. 188 For example, a Managed Access Agreement for
cancer drugs establishes a framework where manufacturers know from

180. Id.
181. Seung-Lai Yoo et al., Improving Patient Access to New Drugs in South
Korea: Evaluation of the National Drug Formulary System, 16 INT’L J. ENVTL. RES.
& PUB. HEALTH 288, 290–92 (Jan. 29, 2019).
182. Sachs, supra note 10, at 2309.
183. Id. at 2311.
184. See id. at 2315, 2320–21.
185. See id. at 2339.
186. Id. at 2340.
187. Id.
188. See id. at 2341.
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the beginning the additional clinical requirements for a new drug to to
receive a favorable NICE recommendation for reimbursement. 189
The U.K. model presses companies to demonstrate that new
medicines have strong value. Specifically, it promotes innovation by
delinking approval from reimbursement. 190 This model can help U.S.
policymakers facilitate partnerships where innovation is encouraged
and access is rewarded.
4. Latin America and Asia – Value-Based and Tendering Models
In some Latin American and Asian countries, new medicines and
vaccines are subject to rigorous value-based assessments before they
are considered for government formulary inclusion. 191 These value
assessments incentivize companies to price their products in these
countries far below the price of the identical drug in the U.S. 192 Thus,
pharmaceutical manufacturers have a powerful incentive to offer drugs
at affordable prices because they can gain access to the large population
covered by government-funded national drug plans. 193
Public programs such as childhood immunizations implement
tendering processes. 194 For example, many emerging markets institute
a tendering model where the manufacturer offering the lowest price is
granted country exclusivity to supply its vaccine for a given period of
time. 195 Procurement mechanics vary in these markets resulting in

189. Id.
190. See id. at 2339–40.
191. See Moïse & Docteur, supra note 55, at 19–20.
192. See id. at 30.
193. See id. at 17–18 (explaining that the IMSS, ISSSTE, and Seguro Popular
de Salud cover approximately 100 million people in Mexico); see also Sang Cheol
Seong et al., Data Resource Profile: The National Health Information Database of
the National Health Insurance Service in South Korea, INT’L J. EPIDEMIOLOGY 1, 1
(2016) (highlighting that the NHI covers South Korea’s entire population of
approximately 50 million).
194. See International AIDS Vaccine Initiative [IAVI], Procurement and
Pricing of New Vaccines for Developing Countries, at 4, IAEA Pol’y Brief 16 (August
2008), http://www.rho.org/files/IAVI_vaccine_procurement_pricing.pdf.
195. See Nikolaos Maniadakis et al., Shaping Pharmaceutical Tenders for
Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage,
16 APPLIED HEALTH ECON. & HEALTH POL’Y 592, 592–94 (2018).
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some of the lowest available prices in the world. 196 However, in the
U.S., the Centers for Disease Control (“CDC”) procurement process for
childhood vaccines establishes in some cases dual suppliers to help
ensure consistent supply of vaccines even when vaccine prices might
increase from year to year. 197
F. Summary – Practical Policy Reform Options in the United States
The challenge for the U.S. in adopting the best practices discussed
above is that currently, the U.S. has a fundamentally different
healthcare system. Despite the challenges that will inevitably come
with overhaul, policymakers should consider other countries’ models
because they can produce meaningful reform. The U.S. should
prioritize instituting reference-based pricing, promoting effective
competition for innovation through a value-based regulatory and
reimbursement system, and enforcing competition laws including the
excessive pricing doctrine.
CONCLUSION
There is no question that given the problem of drug pricing in the
U.S., reform is inevitable. But the devil is always in the details—the
specifics of when and how this reform will be introduced, along with
the reform’s impact, are open questions. Many countries have
implemented reform measures which provide access to new and lifesaving drugs at affordable costs. 198 Countries differ on approaches and
there is no one-size-fits-all model that meets the needs of all markets.
Generally, most countries implement some form of drug pricing
regulations. However, the U.S. is an exception with limited drug price
regulations. These limited regulations drive up the cost of patented
196. Secretariat of the World Health Organization, Global Vaccine Action
Plan: Monitoring, Evaluation & Accountability Subchapter 4: Vaccine Price and
Procurement
Report
2017
148,
152,
https://www.who.int/immunization/global_vaccine_action_plan/gvap_2017_secretar
iat_report_vaccine_prices.pdf.
197.
See
CDC
Vaccine
Price
List,
CDC,
https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/pricelist/index.html (last updated Mar. 1, 2019) (listing childhood vaccines and the
suppliers of those vaccines).
198. See supra Part III Section E.
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innovative drugs to thousands of dollars per year, which results in many
patients not having access to medicine developed in their own
country. 199 However, this Note highlights that the very same pill sold
in the U.S. will often be far less expensive abroad because of
commercial strategies or government-imposed regulations, which can
result in higher patient access. 200 U.S. policymakers should examine
these strategies, and others found to be successful internationally, while
also leveraging its own best practices. In doing so, the U.S. can achieve
drug pricing reform for the benefit of all its citizens.

199.
200.

See generally Patel, supra note 9, at 206.
See supra Part III Section E.
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Notwithstanding the policy reform issues that remain in the U.S.,
one thing is certain: meaningful change will happen when the
government, manufacturers, and payers strive to achieve the common
goal of access to innovative drugs for all those in need.
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